header
Image from OpenLibrary

Evaluation of growth hormone efficacy in the different indication of growth hormone deficiency / Eatemad Helmy Moubarak ; Supervised Abeer Atef Elashmawy , Sahar Yassin Ibrahim , Nora Elsaid Badawy

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Eatemad Helmy Moubarak , 2018Description: 186 P. : charts ; 25cmOther title:
  • تقييم فعالية هرمون النمو كمؤشر فى مختلف أمراض نقص هرمون النمو [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Pediatrics Summary: Background: Short stature is one of the commonest chronic problems encountered in pediatric practice. Objectives: To study the characteristic anthropometric and demographic criteria for the GH therapy (GHT) in Egyptian health insurance regarding etiology and response to GH therapy and to determine the cost benefit value of GHT in the different GH indications. Subject and methods: In this retrospective study 500 short children treated with recombinant GH were examined for growth assessments and response to GHT. Patients were classified into turner syndrome (TS), growth hormone deficiency (GHD), Idiopathic short stature (ISS), silver russell syndrome, multiple pituitary hormonal deficiency (MPHD) and small for gestational age (SGA). Results: Patients with complete GHD had a better growth response (GV/year) (0.76±2.74 SDS) than patients with partial GHD (0.14±1.67 SDS), Patients with GHD had height gain (6.15±1.63 cm) higher than patients with ISS (5.92±1.34 cm), There was significant difference regarding the cost of GH therapy / year (P- value =0.01), as it was higher in patients with ISS than patients with GHD, Girls of Turner syndrome have a better chance for height gain and it is better to be referred to their growth standards and The most significant factors affecting the gain height were age at diagnosis, height at presentation SDS, dose of GH mg/kg/d, duration of therapy and peak of GH by clonidine
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.28.Ph.D.2018.Ea.E (Browse shelf(Opens below)) Not for loan 01010110076693000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.28.Ph.D.2018.Ea.E (Browse shelf(Opens below)) 76693.CD Not for loan 01020110076693000

Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Pediatrics

Background: Short stature is one of the commonest chronic problems encountered in pediatric practice. Objectives: To study the characteristic anthropometric and demographic criteria for the GH therapy (GHT) in Egyptian health insurance regarding etiology and response to GH therapy and to determine the cost benefit value of GHT in the different GH indications. Subject and methods: In this retrospective study 500 short children treated with recombinant GH were examined for growth assessments and response to GHT. Patients were classified into turner syndrome (TS), growth hormone deficiency (GHD), Idiopathic short stature (ISS), silver russell syndrome, multiple pituitary hormonal deficiency (MPHD) and small for gestational age (SGA). Results: Patients with complete GHD had a better growth response (GV/year) (0.76±2.74 SDS) than patients with partial GHD (0.14±1.67 SDS), Patients with GHD had height gain (6.15±1.63 cm) higher than patients with ISS (5.92±1.34 cm), There was significant difference regarding the cost of GH therapy / year (P- value =0.01), as it was higher in patients with ISS than patients with GHD, Girls of Turner syndrome have a better chance for height gain and it is better to be referred to their growth standards and The most significant factors affecting the gain height were age at diagnosis, height at presentation SDS, dose of GH mg/kg/d, duration of therapy and peak of GH by clonidine

Issued also as CD

There are no comments on this title.

to post a comment.